Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
manilatimes4 小时
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed- ...